Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

sapanisertib 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrent Malignant Solid Neoplasm × sapanisertib × Clear all
NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
35 enrolled
Other solid neoplasm

Recurrent Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡